Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
The gene p53 encodes a transcriptional activator of genes involved in growth arrest, DNA repair and apoptosis. Loss of p53 function contributes to tumour development in vivo. The transcriptional activation function of p53 is inactivated by interaction with the mdm2 gene product. Amplification of mdm2 has been observed in 36% of human sarcomas, indicating that it may represent an alternative mechanism of preventing p53 function in tumour development. To study mdm2 function in vivo, we generated an mdm2 null allele by homologous recombination. Mdm2 null mice are not viable, and further analysis revealed embryonic lethality around implantation. To examine the importance of the interaction of MDM2 with p53 in vivo, we crossed mice heterozygous for mdm2 and p53 and obtained progeny homozygous for both p53 and mdm2 null alleles. Rescue of the mdm2-/- lethality in a p53 null background suggests that a critical in vivo function of MDM2 is the negative regulation of p53 activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mdm2 can recruit HDAC1 to p53 to remove these acetylation marks and allow for p53 ubiquitination and degradation [49] in in vitro and mouse models [47,50].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [50]
In the citing paper
“Loss of Mdm2 leads to cell death by apoptosis and embryonic lethality at the blastocyst stage, and this phenotype is completely rescued by concomitant deletion of p53 (Chavez-Reyes, et al., 2003; Jones, et al., 1995; Montes de Oca Luna, et al., 1995).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Montes de Oca Luna, et al., 1995
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [107]
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108 and that they exert non-overlapping inhibitory activities towards p53 (Refs 24,109).”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [107]
In the citing paper
“The crucial importance of MDM2 in regulating p53 was demonstrated using Mdm2-null mice, which display very early embryonic lethality (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
From p53 at a glance (2010) · cites this paper as Montes de Oca Luna et al., 1995
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Thymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
Research works printed but not linked: 1
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 101–200 of 1,001
Stress Signals Utilize Multiple Pathways To Stabilize p53
Ashcroft, M., Taya, Y., & Vousden, K. H. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3224-3233.2000 · Cited by 356
“The importance of regulation of p53 by MDM2 during normal development is dramatically illustrated by the complete rescue of the early embryonic lethality of MDM2deficient mice by simultaneous deletion of p53 (24, 35).”
BackgroundEfstratiadis, A. (1998) · The International Journal of Developmental Biology · doi:10.1387/ijdb.9853827 · Cited by 343
p53-independent functions of the p19ARF tumor suppressor
Weber, J. D., Jeffers, J. R., Rehg, J. E., Randle, D. H., Lozano, G., Roussel, M. F., Sherr, C. J., & Zambetti, G. P. (2000) · Genes & Development · doi:10.1101/gad.827300 · Cited by 354
Self-citationKeeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
Marine, J.-C., Francoz, S., Maetens, M., Wahl, G., Toledo, F., & Lozano, G. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401912 · Cited by 352
Self-citationp53 — a Jack of all trades but master of none
Junttila, M. R., & Evan, G. I. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2728 · Cited by 345
The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344
“Remarkably, deletion of p53 completely rescues this phenotype (Jones et al. 1995; Montes de Oca Luna et al. 1995).”
Backgroundp53-Mediated Hematopoietic Stem and Progenitor Cell Competition
Bondar, T., & Medzhitov, R. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.002 · Cited by 342
Activation of the p53 tumor suppressor protein
Vousden, K. H. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00035-5 · Cited by 337
MDM2 suppresses p73 function without promoting p73 degradation
Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Oren, M., Chen, J., & Lu, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3257 · Cited by 334
“The physiological relationship between p53 and MDM2 is further supported by studies of p53/mdm2 double-knockout mice in which the early embryonic death of mdm2 null mice was rescued by further deleting the p53 gene (25, 44).”
BackgroundZebrafish: A new model on the pharmaceutical catwalk
Langheinrich, U. (2003) · BioEssays · doi:10.1002/bies.10326 · Cited by 332
p53 Acetylation: Regulation and Consequences
Reed, S., & Quelle, D. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 332
The p53 response to DNA damage
Meek, D. W. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.027 · Cited by 329
Novel Insights into Mesothelioma Biology and Implications for Therapy
Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.42 · Cited by 324
Woods, D. B., & Vousden, K. H. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5141 · Cited by 319
Lin, Z., Yang, H., Kong, Q., Li, J., Lee, S.-M., Gao, B., Dong, H., Wei, J., Song, J., Zhang, D. D., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.03.024 · Cited by 315
“The ubiquitinated protein is not likely from Sirt1-binding partners because it was not affected by denaturing Sirt1-ubiquitin conjugates in the presence of 1% SDS ubiquitination lysis buffer (Figure S2D).”
BackgroundMigliorini, D., Denchi, E. L., Danovi, D., Jochemsen, A., Capillo, M., Gobbi, A., Helin, K., Pelicci, P. G., & Marine, J.-C. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5527-5538.2002 · Cited by 313
Activation and activities of the p53 tumour suppressor protein
Bálint, É., & Vousden, K. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2128 · Cited by 313
“…is illustrated by the observation that MDM2 deficiency causes early embryonic lethality in mice which is rescued in the p53-null background (Jones et al, 1995; Montes de Oca Luna et al, 1995), indicating that in the absence of MDM2, unrestrained p53 activity blocks normal growth and development.”
BackgroundMDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
Bond, G., Hu, W., & Levine, A. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 308
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300
Foundations in Cancer Research p53 and ATM: Cell Cycle, Cell Death, and Cancer
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60095-0 · Cited by 300
The Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 296
Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function
Korgaonkar, C., Hagen, J., Tompkins, V., Frazier, A. A., Allamargot, C., Quelle, F. W., & Quelle, D. E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1258-1271.2005 · Cited by 292
“p53 is a transcription factor that activates numerous growth suppressive genes in response to cellular stresses (34), whereas Mdm2 is a p53-responsive gene that encodes an E3 ubiquitin ligase that plays a critical role in restricting p53 activity (50, 51).”
BackgroundNQO1 stabilizes p53 through a distinct pathway
Asher, G., Lotem, J., Kama, R., Sachs, L., & Shaul, Y. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052706799 · Cited by 291
Trim24 targets endogenous p53 for degradation
Allton, K., Jain, A. K., Herz, H.-M., Tsai, W.-W., Jung, S. Y., Qin, J., Bergmann, A., Johnson, R. L., & Barton, M. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813177106 · Cited by 292
“Mdm2 is clearly chief among the previously identified negative regulators of p53 levels, for example, PirH2, ARF-BP1, Cop1, and others (17, 18, 35).”
BackgroundOncogenic ras and p53 Cooperate To Induce Cellular Senescence
Ferbeyre, G., de Stanchina, E., Lin, A. W., Querido, E., McCurrach, M. E., Hannon, G. J., & Lowe, S. W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3497-3508.2002 · Cited by 290
The multiple levels of regulation by p53 ubiquitination
Lee, J. T., & Gu, W. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.77 · Cited by 289
Regulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 288
The INK4a/ARF tumor suppressor: one gene—two products—two pathways
Chin, L., Pomerantz, J., & DePinho, R. A. (1998) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01236-5 · Cited by 288
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Bernal, F., Wade, M., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 285
“Genetic studies demonstrated that MDM2 and MDM4/MDMX exert protein interaction-mediated control over p53 activity through largely nonoverlapping mechanisms (Itahana et al., 2007; Jones et al., 1995; Montes de Oca Luna et al., 1995; Parant et al., 2001).”
Stabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein
Sharp, D. A., Kratowicz, S. A., Sank, M. J., & George, D. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.53.38189 · Cited by 286
Huang, W., Zhang, J., Washington, M., Liu, J., Parant, J. M., Lozano, G., & Moore, D. D. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0520 · Cited by 284
Self-citationRETRACTED: hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage
Moumen, A., Masterson, P., O'Connor, M. J., & Jackson, S. P. (2005) · Cell · doi:10.1016/j.cell.2005.09.032 · Cited by 350
RetractedThe impact of acetylation and deacetylation on the p53 pathway
Brooks, C. L., & Gu, W. (2011) · Protein & Cell · doi:10.1007/s13238-011-1063-9 · Cited by 280
“5 (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
To die or not to die: how does p53 decide?
Slee, E. A., O'Connor, D. J., & Lu, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207516 · Cited by 278
“In zebra fish, for example, Mdm2deficient embryos suffer from a massive increase in apoptosis and this is rescued by knocking down the levels of p53, in much the same way that the embryonic lethal phenotype of Mdm2 null mice can be rescued by crossing with p53 knockout mice (de Oca Luna et al., 1995; Langheinrich et a…”
BackgroundRepression of p53-mediated transcription by MDM2: a dual mechanism
Thut, C. J., Goodrich, J. A., & Tjian, R. (1997) · Genes & Development · doi:10.1101/gad.11.15.1974 · Cited by 272
Rhabdomyosarcoma – working out the pathways
Merlino, G., & Helman, L. J. (1999) · Oncogene · doi:10.1038/sj.onc.1203038 · Cited by 271
“The functional relationship between these two is dramatically corroborated by the ®nding that p53 de®ciency rescues the lethality observed in MDM2 null embryos (Montes de Oca Luna et al., 1995; Jones et al., 1995).”
BackgroundAn Shp2/SFK/Ras/Erk Signaling Pathway Controls Trophoblast Stem Cell Survival
Yang, W., Klaman, L. D., Chen, B., Araki, T., Harada, H., Thomas, S. M., George, E. L., & Neel, B. G. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.01.002 · Cited by 263
Meulmeester, E., Maurice, M. M., Boutell, C., Teunisse, A. F. A. S., Ovaa, H., Abraham, T. E., Dirks, R. W., & Jochemsen, A. G. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.024 · Cited by 260
Osteoblast differentiation and skeletal development are regulated by Mdm2–p53 signaling
Lengner, C. J., Steinman, H. A., Gagnon, J., Smith, T. W., Henderson, J. E., Kream, B. E., Stein, G. S., Lian, J. B., & Jones, S. N. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200508130 · Cited by 265
“…lethality by deletion of p53 demonstrates that Mdm2 plays an important role in early development by negatively regulating p53 activity (Jones et al., 1995; Montes de Oca Luna et al., 1995), on A ugust 18, 2017 jcb.rupress.org D ow nloaded from MDM2–P53 REGULATION OF OSTEOGENESIS • LENGNER ET AL.”
BackgroundDonati, G., Peddigari, S., Mercer, C. A., & Thomas, G. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.05.045 · Cited by 262
“To determine whether all three components interact independent of Hdm2, we took advantage of mouse embryo fibroblasts (MEFs) from Mdm2 / /p53 / -deficient mice (Montes de Oca Luna et al., 1995) treated with a low dose of actinomycin D to impair ribosome biogenesis.”
BackgroundThe Chaperone-associated Ubiquitin Ligase CHIP Is Able to Target p53 for Proteasomal Degradation
Esser, C., Scheffner, M., & Höhfeld, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501574200 · Cited by 261
Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo
Francoz, S., Froment, P., Bogaerts, S., De Clercq, S., Maetens, M., Doumont, G., Bellefroid, E., & Marine, J.-C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508476103 · Cited by 260
ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage
Chen, L., Gilkes, D. M., Pan, Y., Lane, W. S., & Chen, J. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600812 · Cited by 260
“ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage”
BackgroundThe E2F transcription factors: key regulators of cell proliferation
Müller, H., & Helin, K. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(99)00030-x · Cited by 260
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 256
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo
Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.010 · Cited by 256
“Given the well-described toxicity of unfettered p53 during early mouse embryonic development of mdm2-deficient mice (Jones et al., 1995; Montes de Oca Luna et al., 1995) this Figure 7.”
BackgroundMidgley, C. A., Desterro, J. M., Saville, M. K., Howard, S., Sparks, A., Hay, R. T., & Lane, D. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203593 · Cited by 252
“…knockout Mdm2 expression in transgenic mice resulted in non-viability, presumably due to unregulated p53 activity, while p53/Mdm2 double knockout mice were viable although susceptible to developing tumours in a manner similar to p53 knockouts (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
BackgroundTargeting p53 for Novel Anticancer Therapy
Wang, Z., & Sun, Y. (2010) · Translational Oncology · doi:10.1593/tlo.09250 · Cited by 250
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Carvajal, L. A., Neriah, D. B., Senecal, A., Benard, L., Thiruthuvanathan, V., Yatsenko, T., Narayanagari, S.-R., Wheat, J. C., Todorova, T. I., Mitchell, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao3003 · Cited by 249
Mechanism of p53 stabilization by ATM after DNA damage
Cheng, Q., & Chen, J. (2010) · Cell Cycle · doi:10.4161/cc.9.3.10556 · Cited by 248
“Although additional E3 ligases (Pirh2, Cop1) have also been shown to degrade p53 in cell culture,(2,3) mouse models of MDM2 gene knock out provided unequivocal evidence that MDM2 function is indispensable for controlling p53 activity at all stages of life.(4,5) The role of MDM2 as an important regulator of p53 stabili…”
BackgroundUSP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses
Zou, Q., Jin, J., Hu, H., Li, H. S., Romano, S., Xiao, Y., Nakaya, M., Zhou, X., Cheng, X., Yang, P., et al. (2014) · Nature Immunology · doi:10.1038/ni.2885 · Cited by 247
Self-citationLane, D. P., Cheok, C. F., & Lain, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001222 · Cited by 246
Itahana, K., Mao, H., Jin, A., Itahana, Y., Clegg, H. V., Lindström, M. S., Bhat, K. P., Godfrey, V. L., Evan, G. I., & Zhang, Y. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.09.007 · Cited by 245
“Mice with targeted deletion of the Mdm2 gene die during early embryonic development, and this lethality can be rescued by concomitant deletion of p53, indicating that the embryonic lethality of Mdm2 null mice is due to activation of p53 (Jones et al., 1995; Luna et al., 1995).”
BackgroundInfluentialThe Role of MDM2 Amplification and Overexpression in Tumorigenesis
Oliner, J. D., Saiki, A. Y., & Caenepeel, S. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026336 · Cited by 246
“In vivo confirmation that MDM2 antagonizes p53 function came from mouse knockout studies in which p53 deletion rescued the embryonic lethality of MDM2-null mice (Jones et al. 1995; Montes de Oca Luna et al. 1995).”
BackgroundMDM2 promotes ubiquitination and degradation of MDMX
Pan, Y., & Chen, J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.15.5113-5121.2003 · Cited by 246
“Knock out of MDM2 in mice results in embryonic lethality due to hyperactivation of p53 (20).”
BackgroundThe Multifaceted Roles of USP7: New Therapeutic Opportunities
Nicholson, B., & Suresh Kumar, K. G. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9185-5 · Cited by 240
Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy
Zhao, Y., Morgan, M. A., & Sun, Y. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5795 · Cited by 238
“Acting as a major ubiquitin E3 ligase, MDM2 promotes p53 polyubiquitylation and proteasomal degradation with its physiological relevance demonstrated by the full rescue of embryonic lethality in Mdm2-null mice by the loss of p53 (20, 55).”
BackgroundCellular Senescence: Molecular Mechanisms, In Vivo Significance, and Redox Considerations
Muller, M. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2104 · Cited by 238
Lundgren, K., Montes de Oca Luna, R., McNeill, Y. B., Emerick, E. P., Spencer, B., Barfield, C. R., Lozano, G., Rosenberg, M. P., & Finlay, C. A. (1997) · Genes & Development · doi:10.1101/gad.11.6.714 · Cited by 235
Self-citationmdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation
Mendrysa, S. M., McElwee, M. K., Michalowski, J., O'Leary, K. A., Young, K. M., & Perry, M. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.462-473.2003 · Cited by 234
“The mdm2 gene is essential for murine development unless the p53 tumor suppressor gene is inactivated (21, 43).”
BackgroundSTAT-1 Interacts with p53 to Enhance DNA Damage-induced Apoptosis
Townsend, P. A., Scarabelli, T. M., Davidson, S. M., Knight, R. A., Latchman, D. S., & Stephanou, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m302637200 · Cited by 234
p53-Mdm2--the affair that never ends
Alarcon-Vargas, D. (2002) · Carcinogenesis · doi:10.1093/carcin/23.4.541 · Cited by 233
Marine, J.-C. W., Dyer, M. A., & Jochemsen, A. G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03362 · Cited by 228
“Mdm2-deficient mice die very early in development prior to implantation, whereas mice lacking both p53 and Mdm2 are viable and indistinguishable from mice lacking only p53 (Montes de Oca Luna et al., 1995; Jones et al., 1995).”
Backgroundp53 Regulates Cell Cycle and MicroRNAs to Promote Differentiation of Human Embryonic Stem Cells
Jain, A. K., Allton, K., Iacovino, M., Mahen, E., Milczarek, R. J., Zwaka, T. P., Kyba, M., & Barton, M. C. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001268 · Cited by 227
“HDM2, which is embryonicly lethal when deleted (as mdm2) in mice [37], and TRIM24, a negative regulator of p53 identified in mESCs [38], are associated with p53 in pluripotent hESCs but dissociate after RA addition (Figure 2E).”
Cadwell, C., & Zambetti, G. P. (2001) · Gene · doi:10.1016/s0378-1119(01)00696-5 · Cited by 225
p53-family proteins and their regulators: hubs and spokes in tumor suppression
Collavin, L., Lunardi, A., & Del Sal, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2010.35 · Cited by 220
Bouvard, V., Zaitchouk, T., Vacher, M., Duthu, A., Canivet, M., Choisy-Rossi, C., Nieruchalski, M., & May, E. (2000) · Oncogene · doi:10.1038/sj.onc.1203366 · Cited by 220
“The mdm2 basal mRNA expression appears relatively moderate in all the organs studied, in agreement with previous ®ndings (Montes de Oca Luna et al., 1995).”
Resultp300 and CBP: Partners for life and death
Giordano, A., & Avantaggiati, M. L. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199911)181:2<218::aid-jcp4>3.0.co;2-5 · Cited by 291
Efficient p53 Activation and Apoptosis by Simultaneous Disruption of Binding to MDM2 and MDMX
Hu, B., Gilkes, D. M., & Chen, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1140 · Cited by 213
Shi, D., & Gu, W. (2012) · Genes & Cancer · doi:10.1177/1947601912455199 · Cited by 191
NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
Liu, X., Tan, Y., Zhang, C., Zhang, Y., Zhang, L., Ren, P., Deng, H., Luo, J., Ke, Y., & Du, X. (2016) · EMBO reports · doi:10.15252/embr.201540505 · Cited by 214
“Mdm2 is a ubiquitin ligase which functions as an essential inhibitor of p53 [6–8].”
BackgroundRelevance of the p53–MDM2 axis to aging
Wu, D., & Prives, C. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.187 · Cited by 215
Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination
Yan, C., Lu, D., Hai, T., & Boyd, D. D. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600712 · Cited by 214
“The main physiological antagonist of p53 is the MDM2 protein (Jones et al, 1995; Montes et al, 1995; Haupt et al, 1997; Kubbutat et al, 1997), which binds to the amino-terminus of the tumor suppressor and catalyzes the addition of ubiquitin moieties to lysine residues at positions 370, 372, 373, 381, 382 and 386 at th…”
BackgroundMdmX Protects p53 from Mdm2-Mediated Degradation
Jackson, M. W., & Berberich, S. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.1001-1007.2000 · Cited by 211
“Furthermore, even though the role for MdmX during development has not been addressed, MdmX clearly is unable to compensate for the early embryonic lethality observed in Mdm2 null mice (15, 22).”
BackgroundTumor suppression and normal aging in mice with constitutively high p53 activity
Mendrysa, S. M., O'Leary, K. A., McElwee, M. K., Michalowski, J., Eisenman, R. N., Powell, D. A., & Perry, M. E. (2006) · Genes & Development · doi:10.1101/gad.1378506 · Cited by 210
“Mdm2 is a critical survival factor as evidenced by the embryonic death of mice lacking Mdm2 (Jones et al. 1995; Montes de Oca Luna et al. 1995) and the lymphopenia of mice expressing ∼30% of the wild-type level of Mdm2 (Mendrysa et al. 2003).”
BackgroundRegulation of Rap2A by the Ubiquitin Ligase Nedd4-1 Controls Neurite Development
Kawabe, H., Neeb, A., Dimova, K., Young, S. M., Takeda, M., Katsurabayashi, S., Mitkovski, M., Malakhova, O. A., Zhang, D.-E., Umikawa, M., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.01.007 · Cited by 209
“…the reported conventional KO mice lacking ubiquitously expressed E3 ubiquitin ligases (Bloom et al., 2007; Jiang et al., 1998; Lotz et al., 2004; Montes de Oca Luna et al., 1995; Yamashita et al., 2005; Yao et al., 2007), the Nedd4-1-KO exhibits one of the most severe mutant phenotypes,…”
BackgroundE3 Ubiquitin Ligases as Cancer Targets and Biomarkers
Sun, Y. (2006) · Neoplasia · doi:10.1593/neo.06376 · Cited by 205
Inuzuka, H., Tseng, A., Gao, D., Zhai, B., Zhang, Q., Shaik, S., Wan, L., Ang, X. L., Mock, C., Yin, H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.015 · Cited by 204
“The importance of Mdm2 in p53 regulation is further illustrated by the fact that the embryonic lethal phenotype in Mdm2 knockout mice can be partially rescued by further inactivation of the p53 protein (Montes de Oca Luna et al., 1995).”
Targeting the p53–MDM2 interaction to treat cancer
Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204
“This is strongly supported by the observation that embryonic lethality of mdm2-null mice can be reversed only by the simultaneous deletion of the p53 gene (Jones et al, 1995; Monies de Oca Luna et al, 1995).”
BackgroundUSP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan, Y.-H., Cheng, J., Vasudevan, S. A., Dou, J., Zhang, H., Patel, R. H., Ma, I. T., Rojas, Y., Zhao, Y., Yu, Y., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.400 · Cited by 199
FBXO11 Promotes the Neddylation of p53 and Inhibits Its Transcriptional Activity
Abida, W. M., Nikolaev, A., Zhao, W., Zhang, W., & Gu, W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609001200 · Cited by 203
p53 Signaling and Cell Cycle Checkpoints
Stewart, Z. A., & Pietenpol, J. A. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000199t · Cited by 202
Toledo, F., Krummel, K. A., Lee, C. J., Liu, C.-W., Rodewald, L.-W., Tang, M., & Wahl, G. M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.014 · Cited by 199
“5 days post coitum (dpc), due to elevated apoptosis (Jones et al., 1995; Montes de Oca Luna et al., 1995) that is partially rescued by Bax deficiency (Chavez-Reyes et al., 2003).”
BackgroundMDM2 Acts Downstream of p53 as an E3 Ligase to Promote FOXO Ubiquitination and Degradation
Fu, W., Ma, Q., Chen, L., Li, P., Zhang, M., Ramamoorthy, S., Nawaz, Z., Shimojima, T., Wang, H., Yang, Y., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m901758200 · Cited by 201
Olsson, A., Manzl, C., Strasser, A., & Villunger, A. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402196 · Cited by 200
“So far, ubiquitination of p53 by MDM2 is the only posttranslational modification that has been confirmed to be also highly relevant in vivo.(93,94) This does not mean that the others are irrelevant or do not occur in vivo (meaning in a living organism, not cells in the culture dish), but nature appears to be able to c…”
BackgroundRole of T antigen interactions with p53 in tumorigenesis
Pipas, J. M., & Levine, A. J. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0343 · Cited by 199
Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1
Sun, X., Challagundla, K. B., & Dai, M. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.434 · Cited by 195
20 years studying p53 functions in genetically engineered mice
Donehower, L. A., & Lozano, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2731 · Cited by 168
“In 1995 our laboratories showed that aberrant expression of p53 could affect development using Mdm2 -knockout mic”
MethodSelf-citationJuven-Gershon, T., & Oren, M. (1999) · Molecular Medicine · doi:10.1007/bf03402141 · Cited by 194
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z.-G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102309108 · Cited by 193
“The importance of MDM2 in p53 control is highlighted by the finding thatMdm2 knockout results in p53-dependent embryonic lethality in mice (2, 3).”
BackgroundRegulation of Mdm2-Directed Degradation by the C Terminus of p53
Kubbutat, M. H. G., Ludwig, R. L., Ashcroft, M., & Vousden, K. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5690 · Cited by 193
“The importance of Mdm2 in regulating p53 function during normal growth and development is illustrated by the observation that deletion of Mdm2 in mice results in very early embryonic lethality, which is rescued by simultaneous deletion of p53 (29, 46).”
Background(2002) · PubMed
Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR
Winter, M., Sombroek, D., Dauth, I., Moehlenbrink, J., Scheuermann, K., Crone, J., & Hofmann, T. G. (2008) · Nature Cell Biology · doi:10.1038/ncb1743 · Cited by 190
“Therefore, we used mdm2;p53 double-knockout cell”
Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy
Li, Q., & Lozano, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0053 · Cited by 190
Self-citationE2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2.
Kowalik, T. F., DeGregori, J. V., Leone, G. W., Jakoi, L., & Nevins, J. R. (1998) · PubMed · Cited by 190
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3
Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189
“The importance of Mdm2, the mouse isoform of Hdm2, in regulating p53 is shown by the embryonic lethality of mdm2 deletion (7, 8), which is specific for the loss of Mdm2-mediated p53 inhibition as deletion of both p53 and mdm2 results in viable animals that have an increased frequency of tumors similar to those with p5…”
BackgroundComparative study of the p53-mdm2 and p53-MDMX interfaces
Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189
“MDMX can obviously not compensate for lack of mdm2 function during early stages of embryonic development as mdm2 knockout experiments suggest (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
BackgroundMdmx as an essential regulator of p53 activity
Marine, J.-C., & Jochemsen, A. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.151 · Cited by 188
Brooks, C. L., & Gu, W. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.05.022 · Cited by 186
Chibaya, L., Karim, B., Zhang, H., & Jones, S. N. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003193118 · Cited by 182
“UnlikeMdm2-null mice which are embryonic lethal (19, 20), homozygous Mdm2 and Mdm2 (hereafter referred as Mdm2 and Mdm2) mice were viable, fertile, and showed similar body weight to WT mice (SI Appendix, Fig.”
Background
Metadata
- Authors
- de Oca Luna, R. M., Wagner, D. S., & Lozano, G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Venue
- Nature
- Published
- 1995-11
- Volume
- 378
- Issue
- 6553
- Pages
- 203-206
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1969044026
- Semantic Scholar
- e682601f6b2b8de8fa63cc39518a1461943483bc
- Cited by
- 1,420
- References
- 29
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 31 · 2023: 30 · 2022: 31 · 2021: 32 · 2020: 49 · 2019: 29 · 2018: 32 · 2017: 49 · 2016: 63 · 2015: 44 · 2014: 67 · 2013: 37 · 2012: 63
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, MDM2, embryonic lethality, p53-MDM2 interaction, tumor suppressor, sarcoma, homologous recombination, DNA repair
- MeSH terms
- Animals, Base Sequence, Cell Line, Crosses, Genetic, Female, Genes, Lethal, Heterozygote, Homozygote, Male, Mice, Inbred C57BL, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Gene Deletion, DNA Primers, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.